Hormonal Implants Companies

Latest Hormonal Implants Companies Update

August 2022: AVIBELA (levonorgestrel-releasing intrauterine device) 52 mg has been launched in Kenya by Medicines360, MSI Reproductive Choices (MSI), and Marie Stopes Kenya (MSK). Medicines360's hormonal intrauterine device (IUD) is now available in Africa for the third time, following launches in Madagascar and Zambia. Women in Kenya will have more access to an inexpensive and effective long-acting reversible contraception as a result of the collaboration with MSI and MSK. According to research, having additional contraceptive techniques widely available in a nation better serves the requirements of women and couples, resulting in an increase in total contraceptive use. Medicines360, MSI, and MSK are committed to improving access to a wide range of contraception choices in Kenya and across the world. MSK will sell the product to women in Kenya at a cheaper price than was previously accessible in the nation, allowing the product to be spread widely over their networks.

June 2022: Organon, the only worldwide firm of its scale focusing on women's health, celebrated its premiere in June 2022. Organon Canada aspires to be a leader in the field of biosimilars as well as a champion of women's health in Canada. Furthermore, a primary priority for them will be their portfolio of biosimilar medicines, which they anticipate will have a good influence on the sustainability of their healthcare system, particularly as provinces explore new solutions to relieve pressure on healthcare expenses. Organon's portfolio will include more than 60 medicines and products across an international footprint that serves people in more than 140 markets, with nearly 80% of its annual revenue generated outside the United States. Organon is well positioned for organic low-to-mid-single digit growth from its 2021 base of business.  

• Bayer HealthCare


• Shanghai Dahua Pharmaceuticals Co., Ltd


• Merck & Co., Inc.


• Allergan